Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Tue, 12.11.2024       Mainz BioMed N.V.

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets BERKELEY, US and MAINZ, Germany – November 12, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the  [ … ]
Mon, 21.10.2024       Mainz BioMed N.V.

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8 [ … ]
Tue, 08.10.2024       Mainz BioMed N.V.

  Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden   BERKELEY, US and MAINZ, Germany – October 8, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnost [ … ]
Tue, 01.10.2024       Mainz BioMed N.V.

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 BERKELEY, US and MAINZ, Germany – October 1, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to sharehold [ … ]
Wed, 18.09.2024       Mainz BioMed N.V.

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection   BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company” [ … ]
Wed, 18.09.2024       Mainz BioMed N.V.

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection   BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company” [ … ]
Wed, 04.09.2024       Mainz BioMed N.V.

 Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis  BERKELEY, US and MAINZ, G [ … ]
Thu, 25.07.2024       Mainz BioMed N.V.

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience BERKELEY, US – MAINZ, Germany – July 25, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert prod [ … ]
Tue, 09.07.2024       Mainz BioMed N.V.

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clini [ … ]
Tue, 02.07.2024       Mainz BioMed N.V.

Mainz Biomed Provides Half Year 2024 Corporate Update Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study BERKELEY, US – MAINZ, Germany – July 2, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments  [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 21.11.2024, Calendar Week 47, 326th day of the year, 40 days remaining until EoY.